X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15946) 15946
Book Review (1968) 1968
Publication (1105) 1105
Newsletter (132) 132
Conference Proceeding (40) 40
Book Chapter (33) 33
Book / eBook (10) 10
Magazine Article (10) 10
Dissertation (9) 9
Newspaper Article (9) 9
Reference (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14607) 14607
humans (9549) 9549
animals (7622) 7622
female (6534) 6534
male (5984) 5984
mice (5636) 5636
immunology (4700) 4700
interleukin-2 (4357) 4357
middle aged (3460) 3460
adult (3373) 3373
oncology (3318) 3318
immunotherapy (3126) 3126
interleukin-2 - administration & dosage (2808) 2808
aged (2387) 2387
interleukin-2 - therapeutic use (2238) 2238
cancer (1980) 1980
mice, inbred c57bl (1843) 1843
mice, inbred balb c (1747) 1747
lymphocytes (1725) 1725
cytokines (1724) 1724
abridged index medicus (1721) 1721
t-lymphocytes - immunology (1720) 1720
interleukin-2 - pharmacology (1648) 1648
expression (1457) 1457
interleukin-2 - biosynthesis (1415) 1415
t cells (1409) 1409
medicine, research & experimental (1338) 1338
cells, cultured (1333) 1333
interleukin-2 - immunology (1287) 1287
rats (1265) 1265
therapy (1229) 1229
lymphocyte activation (1219) 1219
treatment outcome (1213) 1213
interleukin-2 - metabolism (1206) 1206
pharmacology & pharmacy (1157) 1157
t-lymphocytes, regulatory - immunology (1125) 1125
killer cells, natural - immunology (1117) 1117
recombinant interleukin-2 (1100) 1100
in-vivo (1053) 1053
cd4-positive t-lymphocytes - immunology (1030) 1030
interleukin-2 - adverse effects (998) 998
flow cytometry (997) 997
t-cells (981) 981
il-2 (955) 955
melanoma (938) 938
antineoplastic combined chemotherapy protocols - therapeutic use (930) 930
dendritic cells (925) 925
lymphocyte activation - drug effects (923) 923
transplantation (917) 917
interleukin-2 - genetics (899) 899
time factors (899) 899
care and treatment (896) 896
activation (893) 893
cells (886) 886
research (872) 872
cell biology (858) 858
health aspects (855) 855
dose-response relationship, drug (852) 852
hematology (829) 829
combined modality therapy (824) 824
surgery (814) 814
induction (754) 754
interleukin 2 (731) 731
analysis (719) 719
spleen - immunology (711) 711
adolescent (710) 710
t-lymphocytes - drug effects (708) 708
disease models, animal (700) 700
interferon-gamma - biosynthesis (671) 671
antineoplastic agents - therapeutic use (665) 665
biochemistry & molecular biology (654) 654
cd8-positive t-lymphocytes - immunology (651) 651
antigens (648) 648
regulatory t-cells (647) 647
recombinant proteins - administration & dosage (646) 646
interleukins (640) 640
drug administration schedule (639) 639
spleen - cytology (628) 628
interleukin-2 - blood (624) 624
interferon-gamma (623) 623
neoplasms - therapy (622) 622
article (614) 614
kidney neoplasms - drug therapy (612) 612
antibodies, monoclonal - therapeutic use (608) 608
metastatic melanoma (604) 604
carcinoma, renal cell - drug therapy (601) 601
recombinant proteins - therapeutic use (598) 598
chemotherapy (588) 588
immunotherapy - methods (588) 588
kidney neoplasms - therapy (576) 576
melanoma - drug therapy (574) 574
carcinoma, renal cell - therapy (566) 566
interferon (558) 558
inflammation (557) 557
melanoma - therapy (554) 554
tumors (553) 553
immunity (552) 552
t-lymphocyte subsets - immunology (549) 549
survival (547) 547
aids/hiv (546) 546
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15519) 15519
Japanese (207) 207
Chinese (116) 116
German (80) 80
Russian (67) 67
French (59) 59
Italian (26) 26
Spanish (15) 15
Polish (14) 14
Danish (4) 4
Turkish (3) 3
Dutch (2) 2
Hungarian (2) 2
Korean (2) 2
Romanian (2) 2
Czech (1) 1
Georgian (1) 1
Hebrew (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, pp. e106892 - e106892
Background: CD4(+) T cell is acknowledged as a key factor in the initiation phase of liver ischemia reperfusion injury. The purpose of current study is to... 
RESPONSES | CONTRIBUTE | RANDOMIZED-TRIALS | IMMUNOSUPPRESSION | MULTIDISCIPLINARY SCIENCES | HEPATIC ISCHEMIA/REPERFUSION | INDUCTION | KIDNEY | BASILIXIMAB | LYMPHOCYTES | TRANSPLANTATION | Liver - pathology | CD8-Positive T-Lymphocytes - pathology | Cell Proliferation | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | Interleukin-6 - antagonists & inhibitors | Tumor Necrosis Factor-alpha - genetics | Male | Interleukin-2 - antagonists & inhibitors | CD4-Positive T-Lymphocytes - pathology | CD4-Positive T-Lymphocytes - immunology | Liver - immunology | Interleukin-2 - immunology | Interleukin-2 Receptor alpha Subunit - genetics | Liver - drug effects | Time Factors | Interferon-gamma - antagonists & inhibitors | Tumor Necrosis Factor-alpha - immunology | Interferon-gamma - genetics | Reperfusion Injury - genetics | Interleukin-2 Receptor alpha Subunit - immunology | Gene Expression | Interleukin-6 - genetics | Reperfusion Injury - pathology | Immunomodulation | Mice, Inbred C57BL | Immunophenotyping | CD4 Lymphocyte Count | Interleukin-2 - genetics | Animals | Reperfusion Injury - prevention & control | Antibodies, Monoclonal - administration & dosage | CD8-Positive T-Lymphocytes - drug effects | Interferon-gamma - immunology | Reperfusion Injury - immunology | Interleukin-6 - immunology | Mice | Primary Cell Culture | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Flow cytometry | Transplants & implants | Syngeneic grafts | CD8 antigen | Liver | Immunoglobulin G | Lymphocytes T | Interleukin 6 | Reperfusion | Allografts | Ischemia | Interleukin 2 | Lymphocytes | Rodents | CD25 antigen | Antigens | Damage assessment | Cytokines | Inflammation | Tumor necrosis factor-α | CD4 antigen | Injury prevention | Hepatocytes | γ-Interferon | Monoclonal antibodies | Interferon | Laboratory animals | Immunofluorescence | Binding sites | Liver transplantation | Kidney transplantation | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2003, Volume 21, Issue 21, pp. 3987 - 3994
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2010, Volume 107, Issue 26, pp. 11906 - 11911
IL-2 immunotherapy is an attractive treatment option for certain metastatic cancers. However, administration of IL-2 to patients can lead, by ill-defined... 
Receptors | Lungs | Cell lines | Melanoma | Cellular immunity | Mice | Natural killer cells | Pulmonary edema | Endothelial cells | Tumors | Tumor | T cell | Cytokine/mAb complexes | Cytokine | NK cell | cytokine | IMMUNE-COMPLEXES | MULTIDISCIPLINARY SCIENCES | ANTIBODY | ALPHA | TOXICITY | RENAL-CANCER | tumor | cytokine/mAb complexes | IN-VIVO | BIOLOGICAL-ACTIVITY | REGULATORY T-CELLS | HIGH-DOSE INTERLEUKIN-2 | CD8(+) CELLS | Recombinant Proteins - therapeutic use | Immunotherapy - methods | Interleukin-2 - adverse effects | Homeodomain Proteins - metabolism | Humans | Interleukin-2 - therapeutic use | Interleukin-2 - antagonists & inhibitors | Recombinant Proteins - adverse effects | Lung - cytology | Pulmonary Edema - etiology | Interleukin-2 Receptor alpha Subunit - genetics | Lymphocytes - immunology | Melanoma, Experimental - immunology | Lung Neoplasms - secondary | Interleukin-2 - administration & dosage | Melanoma, Experimental - secondary | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - deficiency | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Receptors, Interleukin-2 - metabolism | Lung Neoplasms - therapy | Homeodomain Proteins - genetics | Recombinant Proteins - administration & dosage | Immunotherapy - adverse effects | Mice, Knockout | Endothelial Cells - immunology | Lung Neoplasms - immunology | Animals | Interleukin-2 Receptor alpha Subunit - metabolism | Antibodies, Monoclonal - administration & dosage | Pulmonary Edema - immunology | Antigen-Antibody Complex - administration & dosage | Antigen-Antibody Complex - immunology | Lung - immunology | Care and treatment | Interleukin-2 | Health aspects | Immunotherapy | Methods | Immunology | Lymphocytes | Rodents | Metastasis | Cells | Cancer | Index Medicus | Biological Sciences | mAb complexes
Journal Article
Blood, ISSN 0006-4971, 06/2014, Volume 123, Issue 25, pp. 3855 - 3863
Journal Article
Journal Article
Clinical cancer research, ISSN 1078-0432, 2011, Volume 17, Issue 17, pp. 5725 - 5735
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 08/2011, Volume 9, Issue 8, pp. 1524 - 1533
See also Miao CH. Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors. This issue, pp 1521–3.DOI:. Summary. ... 
hemophilia | inhibitor | factor VIII | T helper cell | tolerance | rapamycin | Tolerance | Inhibitor | Rapamycin | Factor VIII | Hemophilia | PREVENTION | ANTIGEN-SPECIFIC EFFECTOR | AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME | IMMUNE-RESPONSES | HEMOPHILIA-A MICE | FACTOR-IX | REGULATORY T-CELLS | PERIPHERAL VASCULAR DISEASE | GENE-THERAPY | INHIBITOR DEVELOPMENT | HEME OXYGENASE-1 | HEMATOLOGY | Factor VIII - immunology | Humans | Transforming Growth Factor beta1 - metabolism | Male | Adoptive Transfer | CD4-Positive T-Lymphocytes - immunology | Time Factors | Forkhead Transcription Factors - metabolism | Coagulants - administration & dosage | Interleukin-6 - metabolism | Immunosuppressive Agents - administration & dosage | Disease Models, Animal | Immune Tolerance - drug effects | Interleukin-2 - metabolism | Drug Administration Schedule | Hemophilia A - immunology | Interleukin-4 - metabolism | Mice, Inbred C57BL | Cells, Cultured | CTLA-4 Antigen - metabolism | Hemophilia A - blood | Recombinant Proteins - administration & dosage | Sirolimus - administration & dosage | Animals | CD4-Positive T-Lymphocytes - transplantation | Interleukin-2 Receptor alpha Subunit - metabolism | Factor VIII - administration & dosage | Antibodies - blood | Mice | Mice, Inbred BALB C | Coagulants - immunology | Hemophilia A - drug therapy | CD4-Positive T-Lymphocytes - drug effects | Blood coagulation factor VIII | T cells | Transforming growth factors | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 02/2019, Volume 116, Issue 8, pp. 3100 - 3105
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including regulatory T cells and has been... 
Cancer immunotherapy | Fusion toxin | Tregs | INTERLEUKIN-2 | DENILEUKIN DIFTITOX | SAFETY | MULTIDISCIPLINARY SCIENCES | NK-CELLS | COMBINATION | cancer immunotherapy | fusion toxin | REGULATORY T-CELLS | FRAGMENT | DABIL-2 | PHASE-I | BINDING | Diphtheria Toxin - administration & dosage | Human Umbilical Vein Endothelial Cells - drug effects | Humans | Melanoma, Experimental - drug therapy | Melanoma, Experimental - pathology | Recombinant Fusion Proteins - chemistry | Corynebacterium diphtheriae - chemistry | Corynebacterium diphtheriae - pathogenicity | Interleukin-2 Receptor alpha Subunit - drug effects | Receptors, Interleukin-2 - immunology | Receptors, Interleukin-2 - genetics | Antibodies - administration & dosage | T-Lymphocytes, Regulatory - drug effects | Immunotoxins - administration & dosage | Melanoma, Experimental - genetics | Melanoma, Experimental - immunology | Interleukin-2 - administration & dosage | Amino Acid Substitution - genetics | Interleukin-2 - chemistry | Cell Proliferation - drug effects | Diphtheria Toxin - chemistry | Programmed Cell Death 1 Receptor - genetics | Immunosuppressive Agents - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Cell culture | PD-1 protein | Toxicity | Antibodies | Lymphocytes T | Agglomeration | Anticancer properties | Amino acid substitution | Proteins | Interleukin 2 | Lymphocytes | CD25 antigen | Inhibition | Fusion protein | Interleukin 2 receptors | Immunoregulation | Melanoma | Diphtheria | Lymphoma | Biological activity | Endothelial cells | Immunogenicity | Cell death | Production methods | Antitumor activity | Umbilical vein | T-cell lymphoma | Cancer | Tumors | Apoptosis | Index Medicus | Biological Sciences
Journal Article
Scientific Reports, ISSN 2045-2322, 07/2015, Volume 5, Issue 1, pp. 12633 - 12633
The anti-inflammatory cytokine IL-35 is produced by regulatory T (Treg) cells to suppress autoimmune and inflammatory responses. The role of IL-35 in type 1... 
B-CELLS | AUTOIMMUNE | NEUROPILIN-1 | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION FACTOR FOXP3 | IN-VIVO | HELPER-CELLS | INDUCED ARTHRITIS | TNF-ALPHA | IL-35 | EXPRESSION | Leukocytes, Mononuclear - metabolism | T-Lymphocytes, Regulatory - metabolism | Minor Histocompatibility Antigens | Humans | Diabetes Mellitus, Type 1 - metabolism | Interleukin-10 - blood | Male | Recombinant Proteins - biosynthesis | Interleukins - metabolism | T-Lymphocytes, Regulatory - immunology | Recombinant Proteins - isolation & purification | Interleukins - genetics | Diabetes Mellitus, Experimental - prevention & control | Flow Cytometry | Forkhead Transcription Factors - metabolism | T-Lymphocytes, Helper-Inducer - immunology | T-Lymphocytes, Helper-Inducer - cytology | T-Lymphocytes, Regulatory - cytology | Diabetes Mellitus, Experimental - chemically induced | Receptors, Cytokine - metabolism | Thymus Gland - metabolism | Disease Models, Animal | Interleukin-2 - metabolism | Hyperglycemia - prevention & control | T-Lymphocytes, Helper-Inducer - metabolism | Cytokines - metabolism | Enzyme-Linked Immunosorbent Assay | Interleukins - blood | Diabetes Mellitus, Type 1 - pathology | Transforming Growth Factor beta - blood | Recombinant Proteins - administration & dosage | Diabetes Mellitus, Experimental - immunology | Phenotype | Animals | Interleukins - administration & dosage | Spleen - metabolism | Diabetes Mellitus, Type 1 - blood | Leukocytes, Mononuclear - cytology | Mice, Inbred NOD | Mice | Streptozocin - toxicity | Immunoregulation | Streptozocin | Diabetes mellitus | T cell receptors | Lymphocytes T | Inflammation | Interleukin 17 | Hyperglycemia | Interleukin 2 | Rodents | Interleukin 10 | Interferon | Diabetes | Autoimmune diseases | Index Medicus | Biological Sciences | Naturvetenskap | Natural Sciences | Cellbiologi | Biologiska vetenskaper | Cell Biology
Journal Article